🔎 Trials Near Me

Utama › Kanser (semua jenis) › South Dakota

Kajian klinikal Kanser (semua jenis) di South Dakota

13 kajian untuk Kanser (semua jenis) sedang mencari peserta di lokasi di South Dakota.

Bandar di South Dakota

Teks kajian rasmi (Bahasa Inggeris)

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

  • Sanford Children's Hospital ( Site 4015), Sioux Falls
Mengambil pesertaFasa 1/2
1 Month – 17 Years · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07630974

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls
Mengambil pesertaFasa 2
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT02693535

Connect for Cancer Prevention Study (Connect)

  • Sanford Health, Sioux Falls
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 30 hingga 70 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04609072

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  • Sanford Children's Hospital ( Site 3015), Sioux Falls
Mengambil pesertaFasa 1/2
1 Month – 17 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06941272

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  • Research Site, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 hingga 130 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07647328

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

  • Sanford Sioux Falls, Sioux Falls
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06163534

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  • Sanford Cancer Center Oncology Clinic ( Site 0038), Sioux Falls
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07252739

Project: Every Child for Younger Patients With Cancer

  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Avera Cancer Institute-Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute at Pierre, Pierre
  • dan 4 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT06580314

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

  • Avera Medical Group Gynecologic Oncology Sioux Falls, Sioux Falls
  • Texas Oncology, P.A. - Tyler, Sioux Falls
Mengambil pesertaFasa 3
Umur 18 ke atas · Wanita · Dikemas kini 28 Jul 2026 · NCT07022483

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  • Sanford Clinical Research, Sioux Falls
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT01042379

Avera Cancer Sequencing and Analytics Protocol (ASAP)

  • Avera Cancer Institute - Aberdeen, Aberdeen
  • Avera Cancer Institute - Mitchell, Mitchell
  • Avera Cancer Institute - Pierre, Pierre
  • dan 2 lagi
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Mac 2026 · NCT05142033

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  • Sanford Cancer Center Oncology Clinic, Sioux Falls
  • Sanford USD Medical Center - Sioux Falls, Sioux Falls
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 27 Nov 2024 · NCT03860883

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.